Has the U.S. Biotech Industry valuation changed over the past few years?

Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates. The 3-year average PS ratio of 7.0x is lower than the industry's current PS ratio of 8.8x.

Which industries have driven the changes within the U.S. Healthcare industry?

There are no additional sub-industries under this industry.

U.S. Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 02 Sep 2026	US$1.5t	US$173.0b	-US$20,233,678,846.30	17.3x	-75x	8.8x
Fri, 31 Jul 2026	US$1.4t	US$169.8b	-US$12,491,937,018.30	16.9x	-112.4x	8.3x
Sun, 28 Jun 2026	US$1.4t	US$169.9b	-US$12,062,034,705.15	17.2x	-115.6x	8.2x
Tue, 26 May 2026	US$1.3t	US$170.0b	-US$12,285,000,013.65	16.2x	-105.1x	7.6x
Thu, 23 Apr 2026	US$1.3t	US$166.2b	-US$11,942,531,263.55	17x	-111.3x	8x
Sat, 21 Mar 2026	US$1.3t	US$169.3b	-US$15,282,661,676.77	16.7x	-83.2x	7.5x
Mon, 16 Feb 2026	US$1.3t	US$168.9b	-US$12,914,459,252.42	22.2x	-103.3x	7.9x
Wed, 14 Jan 2026	US$1.2t	US$163.5b	-US$15,154,711,813.01	20.2x	-81x	7.5x
Fri, 12 Dec 2025	US$1.2t	US$163.7b	-US$15,620,268,826.39	19.2x	-77.6x	7.4x
Sun, 09 Nov 2025	US$1.1t	US$163.6b	-US$15,721,529,627.74	17x	-71.9x	6.9x
Tue, 07 Oct 2025	US$1.1t	US$163.5b	-US$18,203,097,730.54	16.5x	-62.3x	6.9x
Thu, 04 Sep 2025	US$1.1t	US$163.5b	-US$18,341,677,831.30	15.5x	-58.6x	6.6x
Sat, 02 Aug 2025	US$1.0t	US$158.3b	-US$21,877,165,347.51	15.8x	-46.2x	6.4x
Mon, 30 Jun 2025	US$927.2b	US$156.0b	-US$23,836,878,936.09	17.2x	-38.9x	5.9x
Wed, 28 May 2025	US$911.8b	US$155.9b	-US$24,111,099,148.63	16x	-37.8x	5.8x
Fri, 25 Apr 2025	US$790.7b	US$119.2b	-US$36,562,802,211.15	20x	-21.6x	6.6x
Sun, 23 Mar 2025	US$827.4b	US$118.6b	-US$36,836,383,348.69	20.4x	-22.5x	7x
Tue, 18 Feb 2025	US$842.1b	US$116.6b	-US$36,838,458,362.91	17.6x	-22.9x	7.2x
Thu, 16 Jan 2025	US$933.0b	US$149.4b	-US$26,288,358,151.10	17x	-35.5x	6.2x
Sat, 14 Dec 2024	US$1.0t	US$150.0b	-US$26,499,023,924.94	16.6x	-37.8x	6.7x
Mon, 11 Nov 2024	US$1.1t	US$149.6b	-US$27,286,902,976.61	16.5x	-40.7x	7.4x
Wed, 09 Oct 2024	US$878.9b	US$113.1b	-US$35,894,198,277.00	20.5x	-24.5x	7.8x
Fri, 06 Sep 2024	US$891.3b	US$113.1b	-US$35,694,163,155.93	22.9x	-25x	7.9x
Sun, 04 Aug 2024	US$1.2t	US$165.8b	-US$32,803,544,510.84	25.9x	-36.7x	7.3x
Tue, 02 Jul 2024	US$1.1t	US$164.4b	-US$27,968,148,950.64	28.8x	-41.1x	7x
Thu, 30 May 2024	US$1.1t	US$164.6b	-US$26,666,955,066.31	26.8x	-41.5x	6.7x
Sat, 27 Apr 2024	US$1.1t	US$164.6b	-US$27,388,073,165.09	22.6x	-39.1x	6.5x
Mon, 25 Mar 2024	US$1.2t	US$164.3b	-US$23,931,097,513.35	21.4x	-48.6x	7.1x
Wed, 21 Feb 2024	US$1.2t	US$169.2b	-US$20,429,726,157.04	15.8x	-56.6x	6.8x
Fri, 19 Jan 2024	US$1.4t	US$204.7b	-US$22,508,448,136.00	18.3x	-63.1x	6.9x
Sun, 17 Dec 2023	US$1.4t	US$204.7b	-US$22,119,635,723.00	19.2x	-61x	6.6x
Tue, 14 Nov 2023	US$1.2t	US$204.5b	-US$21,994,312,170.00	18.6x	-54.7x	5.9x
Thu, 12 Oct 2023	US$1.3t	US$207.4b	-US$13,067,336,949.00	17.4x	-97.2x	6.1x
Sat, 09 Sep 2023	US$1.3t	US$207.5b	-US$12,633,744,533.00	17.4x	-100.7x	6.1x


US Market	-0.92%
Healthcare	-2.56%
Biotech	-2.29%
Biotech	-2.29%

Company	Last Price	7D	1Y	Valuation
GILD Gilead Sciences	US$149.92	0.8% +US$1.4b	33.0%	PS6.1x
ALNY Alnylam Pharmaceuticals	US$246.11	2.5% +US$806.9m	-44.9%	PE42.5x
PURR Hyperliquid Strategies	US$11.36	-4.3% US$648.5m	n/a	PE8.8x
SMMT Summit Therapeutics	US$14.16	6.0% +US$638.2m	-40.6%	PB17.9x
MDGL Madrigal Pharmaceuticals	US$538.71	5.2% +US$613.4m	23.5%	PS9.7x

Announcement • Aug 31

Alnylam Pharmaceuticals Presents New Data On Vutrisiran And Zilebesiran At ESC Congress 2026

Alnylam Pharmaceuticals, Inc. announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension. A late-breaking oral presentation featured a prespecified subgroup analysis of the HELIOS-B Phase 3 clinical trial evaluating the treatment effect of vutrisiran according to baseline tafamidis use. Among 654 randomized and treated patients in HELIOS-B, 259 patients (40%) were receiving tafamidis at baseline. The treatment effect for vutrisiran on the primary composite endpoint of all-cause mortality and recurrent cardiovascular events through 33-36 months was consistent irrespective of baseline tafamidis use, suggesting clinical benefits across broad patient populations, including those receiving stabilizers. All-cause mortality and additional cardiovascular outcomes showed a similar benefit among patients who were receiving tafamidis at baseline (“combination population”) and those who were not (“monotherapy population”). Across both groups, treatment with vutrisiran preserved functional capacity versus placebo, as measured by the Six-Minute Walk Test. Improvement in health status by vutrisiran versus placebo, as measured by the Kansas City Cardiomyopathy Questionnaire-overall summary score, was observed in both the monotherapy and combination populations with an attenuated effect seen among patients receiving tafamidis at baseline. Safety outcomes were generally similar between combination vutrisiran and tafamidis versus tafamidis alone, and between vutrisiran monotherapy versus placebo. HELIOS-B was not powered to establish the benefit of vutrisiran specifically in the population of patients receiving background tafamidis at baseline. These findings reinforce the impact of vutrisiran across contemporary ATTR-CM treatment settings and warrant further evaluation of TTR silencing and stabilization combination strategies. Additional analyses presented at ESC further underscore the multisystemic burden of ATTR-CM and the importance of evaluating measures beyond traditional cardiac endpoints. Real-world evidence from the French National Health Data System showed that patients with ATTR-CM had a significantly higher burden of extra-cardiac manifestations across multiple organ systems compared with matched controls, and multiple manifestations were recorded years before ATTR-CM identification and tended to accumulate over time, suggesting a prolonged pre-diagnostic phase with evolving multisystem involvement. A post hoc analysis of HELIOS-B evaluated the impact of treatment with vutrisiran on intrinsic capacity, a composite measure encompassing locomotion, cognition, vitality, psychological well-being and sensory function aligned with the World Health Organization Integrated Care for Older People framework. In the overall study population, compared with placebo, patients treated with vutrisiran demonstrated 25% less decline from baseline intrinsic capacity score and a 52% reduction in the risk of decline, suggesting that treatment with vutrisiran may help preserve functional reserve and support healthy aging in patients with ATTR-CM. A separate post hoc safety analysis of HELIOS-B showed that patients treated with vutrisiran had fewer adverse events overall compared with placebo across the overall study population, monotherapy population and combination population. Among the most frequent system organ classes in the overall population, the lowest adverse event rate ratios were observed for gastrointestinal disorders and nervous system disorders, with 42% and 41% lower adverse event rates, respectively, with vutrisiran compared with placebo; eye disorders showed a 46% lower event rate with vutrisiran compared with placebo. A pooled analysis of 1,402 patients (203 females, 1,199 males) across four Phase 3 studies of vutrisiran and patisiran further reinforces the clinical benefits of RNAi-mediated TTR silencing across sexes. Despite sex-specific baseline differences in disease presentation, treatment effects were consistent between females and males across both ATTR-CM and the polyneuropathy of hereditary ATTR (hATTR-PN), including clinical, biomarker, functional, health status and echocardiographic measures. The KARDIA-3 Phase 2 study evaluated zilebesiran, an investigational RNAi therapeutic with the potential to provide continuous control of blood pressure (BP) with biannual dosing, in patients with uncontrolled hypertension with high cardiovascular (CV) risk treated with two or more background antihypertensives. In patients who were receiving a background diuretic with an office systolic BP (SBP) =140 mmHg at baseline, zilebesiran achieved greater reductions in mean office and 24-hour ambulatory SBP than in the overall study population. Furthermore, patients treated with zilebesiran experienced SBP reductions across the diurnal cycle, including at nighttime. Similar findings were observed in patients who had impaired nocturnal dipping at baseline. These findings are potentially important given the association between elevated nighttime BP and CV risk. The safety profile in this post hoc subgroup was consistent with the broader zilebesiran Phase 2 program. These findings further support the evaluation of zilebesiran in the ongoing global Phase 3 CV outcomes trial, ZENITH. In the EU, AMVUTTRA (vutrisiran) is indicated for the treatment of hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN) and wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Vutrisiran treatment can lower serum vitamin A levels, therefore supplementation of approximately, but not exceeding, 2,500 IU to 3,000 IU vitamin A per day is advised for patients. Commonly reported adverse reactions with vutrisiran were injection site reactions and increase in blood alkaline phosphatase and alanine transaminase. In the EU, ONPATTRO (patisiran) is indicated for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy. Patisiran treatment can lower serum vitamin A levels, therefore supplementation of approximately, but not exceeding, 2,500 IU to 3,000 IU vitamin A per day is advised for patients. The most common adverse reactions that occurred in patients treated with patisiran were peripheral oedema (30%) and infusion-related reactions (19%). AMVUTTRA (vutrisiran) demonstrates strength in RNAi-powered transthyretin (TTR) silencing, delivering rapid knockdown of TTR at the source of disease to address the underlying cause of transthyretin amyloidosis (ATTR).

U.S. Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Signatera Data Validates Earlier and More Accurate Lymphoma Detection for Natera

BioMarin Pharmaceutical Inc. Announces Global Settlement With Ascendis Pharma A/S

Beone Medicines Announces Positive Topline Results from Second Interim Analysis of Phase 3 Herizon-Gea-01 Trial Evaluating Ziihera in Combination with Chemotherapy with and Without Tevimbra as First-Line Treatment for Her2+ Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Alnylam Pharmaceuticals Presents New Data On Vutrisiran And Zilebesiran At ESC Congress 2026

Repatha Shown to Lower Death Risk in High-Risk Heart Patients in Phase 3 Study

Hyperliquid Strategies Nets $305.5 Million and Expands HYPE Token Holdings With Equity Raise

Moderna Wins FDA Approval for New COVID-19 Vaccines Targeting 2026-2027 Variant

BioNTech SE And Genentech Terminate Phase 2 Clinical Trial Collaboration For Autogene Cevumeran In Resected Colorectal Cancer

Roivant Sciences Wins FDA Clearance for First Targeted Dermatomyositis Therapy LISRAYA

FDA Clears Gilead’s Bixlenvo as New Single Tablet HIV Regimen for Complex Cases

Sarepta: A Prove-It Story Now Defined By ELEVIDYS Execution

Neurocrine Biosciences Advances Alzheimer’s Trial After FDA IND Clearance and $10 Million Milestone

AbbVie Seeks EMA Approval for SKYRIZI Subcutaneous Induction in Crohn’s Disease

Spyre Therapeutics: Catalyst-Rich Period But Easiest Money May Have Been Made (Downgrade)

Summit Therapeutics Awaits FDA Decision After Positive Phase III Ivonescimab Results Published

Madrigal Pharmaceuticals, Inc. Announces Appointment of John C. Reed as Board Director